Clinical Edge Journal Scan

Frequent joint inflammation increases local joint damage progression in early RA


 

Key clinical point: Cumulative local joint inflammation over time was significantly associated with radiographic joint damage progression in the same joint in patients with early rheumatoid arthritis (RA) who were treated to a target disease activity score (DAS) of 2.4 for 10 years.

Major finding: Cumulative joint swelling was positively associated with local joint damage progression in the same joint (β 0.14; 95% CI 0.13-0.15). Each additional visit for joint swelling increased the joint damage score by a 0.13 unit and frequency of joint swelling in same vs other joints better predicted local joint damage progression (P < .001).

Study details: This post hoc analysis of the BeSt study included 473 patients with early RA who were randomly assigned to receive sequential monotherapy, step-up combination therapy, or initial combination therapy with methotrexate with or without sulfasalazine+prednisone or infliximab, with treatment intensification every 3 months until DAS 2.4 was achieved.

Disclosures: The BeSt study received funding from the Dutch College of Health Insurances and others. No competing interests were declared.

Source: Heckert SL et al. Frequency of joint inflammation is associated with local joint damage progression in rheumatoid arthritis despite long-term targeted treatment. RMD Open. 2023;9(1):e002552 (Jan 6). Doi: 10.1136/rmdopen-2022-002552

Recommended Reading

Rituximab worsens COVID-19 outcomes in RA
MDedge Rheumatology
Commentary: Interstitial Lung Disease, Onset Time, and RA, January 2023
MDedge Rheumatology
Best estimates made for hydroxychloroquine retinopathy risk
MDedge Rheumatology
Teamwork guides cardio-rheumatology clinics that care for unique patient population
MDedge Rheumatology
Methotrexate use needs close monitoring in patients with RA of childbearing age
MDedge Rheumatology
Most patients successfully discontinue glucocorticoids after initiation as bridging therapy in RA
MDedge Rheumatology
Oral glucocorticoid use raises risk for Staphylococcus aureus bacteremia in RA
MDedge Rheumatology
Comorbidity burden tied to lower likelihood of achieving quality care in RA
MDedge Rheumatology
Tapering glucocorticoids to ≤2.5 mg/day increases the risk for flare in patients receiving bDMARD in RA
MDedge Rheumatology
Multidisciplinary lifestyle program improves outcomes in RA
MDedge Rheumatology